ABOUT THE NEWSROOM

Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company
solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.

Science
PATIENT VOICES
Our Impact
News Releases
Otsuka Pharmaceutical And Lundbeck Present Positive Data From Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms Of Agitation In Patients With Alzheimer’s Dementia At The 2022 Clinical Trials For Alzheimer’s Disease Congress
News Releases
Otsuka Pharmaceutical And Lundbeck Present Positive Data From Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms Of Agitation In Patients With Alzheimer’s Dementia At The 2022 Clinical Trials For Alzheimer’s Disease Congress
Read Story
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults
News Releases
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults
Read Story
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
News Releases
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
Read Story
Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer’s Dementia at AAIC 2022
News Releases
Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer’s Dementia at AAIC 2022
Read Story
Results from the DELIVER study with VYEPTI® (eptinezumab-jjmr) has been published in a top-ranking medical journal
News Releases
Results from the DELIVER study with VYEPTI® (eptinezumab-jjmr) has been published in a top-ranking medical journal
Read Story

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site are subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. 

© Copyright 2022 Lundbeck. All rights reserved.